Clinical trials: Liver Tumour
Liver Regeneration, Liver Cancer
ARAPS Study on Accelerated Liver Regeneration
Liver resection is the golden standard in the treatment of hepatic malignancies. The size and function of the remnant liver is a major concern.
- Conditions
- Liver Regeneration, Liver Cancer, Liver Metastases, Liver Failure
- Trial name
- ARAPS (NCT04107324)
- Testing
- ARAPS, PVE
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
This phase Ib trial studies the side effects and best dose of autologous CD8 positive (+) SLC45A2-specific T lymphocytes when given together with cyclophosphamide, aldesleukin, and ipilimumab, and to see how well they work in…
- Trial name
- NCT03068624
- Testing
- Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Pulmonary Metastasis
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
This study mainly evaluate the clinical effect of Apatinib in the treatment of patients with pulmonary metastasis of hepatocellular carcinoma.Half of participants will receive Apatinib and transcatheter arterial chemoembolization…
- Trial name
- NCT02702323
- Testing
- Apatinib, TACE
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted…
- Trial name
- NCT07479485
- Testing
- MRG006A, Pucotenlimab, Bevacizumab
- Where
- 8 sites in China
- Volunteers
- 160 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma
Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma
Positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG-PET) evaluates cancer cell glycolysis(Warburg effect) as a surrogate for tumor response.The hypothesis of this study is that early changes in FDG-PET signal can…
- Trial name
- NCT01157013
- Testing
- Positron emission tomography with fludeoxyglucose F 18
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital Miguel Servet
Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
This prospective, multicenter, phase II randomized controlled trial compares the efficacy and safety of SBRT combined with systemic therapy versus systemic therapy alone in BCLC stage C hepatocellular carcinoma (HCC).
- Trial name
- NCT07274774
- Testing
- Systemic therapy, Radiotherapy
- Where
- China
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the Treatment of Patients With Unresectable Hepatocellular Carcinoma.
- Trial name
- NCT05029973
- Testing
- HAIC, Sintilimab, Bevacizumab Biosimilar
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced/Metastatic Hepatocellular Carcinoma
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
This is a single arm and open-label phase I trial to evaluate the safety, tolerability and efficacy of the oncolytic virus M1 （M1-c6v1）(iv 1×109 CCIC50, 1 dose per day, on day 1-5 each 28 day cycle) combined with anti-PD-1…
- Trial name
- NCT04665362
- Testing
- Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
- Volunteers
- 10 people
- Sponsor
- Liang Peng
Pancreatic Cancer With Liver Metastases
Surgical Management of Pancreatic Cancer With Liver Metastasis (Oligometastasis)
Pancreatic cancer is one of the most serious forms of cancer. When it has already spread to the liver, treatment usually consists of chemotherapy rather than surgery.
- Trial name
- POlig (NCT07446946)
- Volunteers
- 68,303 people
- Sponsor
- Richard Hunger
Liver Tumor
Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors
This study will comprise the first pilot clinical trial of 3D, ultrasound-based thermal ablation control using echo decorrelation imaging, directly testing the capability of this approach to ensure reliable tumor treatment.
- Trial name
- NCT05211388
- Testing
- RFA controlled using echo decorrelation imaging, RFA controlled using standard manufacturer-specified algorithms
- Where
- United States
- Sponsor
- University of Cincinnati
Hepatocellular Carcinoma
LiverMultiScan Analysis of MRI Scans in HCC
This project is a pilot study to interrogate the potential of LMS as a predictive tool for the selection of therapy for HCC patients.
- Trial name
- NCT04451603
- Testing
- Surgery, Radiation therapy, Drug treatment
- Where
- Singapore
- Volunteers
- 21 people
- Sponsor
- National Cancer Centre, Singapore
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.
- Trial name
- NCT04104074
- Testing
- Radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatocellular Carcinoma
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment.
- Trial name
- NCT07235410
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma
Resection+Highly Purified CTL Versus Resection Alone for HCC
There is little evidence showed that adjuvant therapy had been shown to extend the survival of patients with hepatocellular carcinoma (HCC) receiving surgical resection.
- Trial name
- NCT02709070
- Testing
- resection, highly-purified CTL
- Volunteers
- 210 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC)
Individualized Surgical Guidance in HCC-BDTT
The Rboost causal model can identify patients who are most likely to benefit among HCC-BDTT patients. Adherence to the individualized recommendation improves survival.
- Trial name
- NCT07483242
- Testing
- Bile Duct Resection
- Where
- China
- Volunteers
- 151 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Nausea and Vomiting, Postoperative, Liver Cancer
A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer
PONV management has been recommended as a necessary part of enhanced recovery protocols during the perioperative period, and PONV risk assessment is, therefore, a necessary first step in determining the number of medications or…
- Trial name
- NCT06356623
- Testing
- 1
- Volunteers
- 476 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Hepatocellular Carcinoma
GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
The hepatocellular carcinoma (HCC) represents more than 5% of all human malignancies, with more than 500,000 deaths per year (1).
- Trial name
- SS-HCC (NCT00495846)
- Testing
- Octreotide-LAR, Lanreotide Autogel, Locoregional treatments
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Federico II University
Hepatocellular Carcinoma, Anti-PD1 Antibody
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC.
- Conditions
- Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases
- Trial name
- NCT04627012
- Testing
- Lenvatinib, Opdivo, Camrelizumab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma
In this study the investigators will be studying the effects of proton beam radiation therapy. This is a very accurate kind of treatment that has been shown to affect less normal tissue than a photon radiation beam.
- Trial name
- NCT00976898
- Testing
- Proton Beam Irradiation
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.